Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.43
-5.68 (-2.70%)
AAPL  267.82
+3.24 (1.22%)
AMD  195.55
-4.60 (-2.30%)
BAC  51.42
-1.64 (-3.08%)
GOOG  313.17
-1.73 (-0.55%)
META  640.01
-15.65 (-2.39%)
MSFT  386.54
-10.69 (-2.69%)
NVDA  191.12
+1.30 (0.68%)
ORCL  140.07
-8.01 (-5.41%)
TSLA  395.25
-16.57 (-4.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.